BTX
Income statement / Annual
Last year (2023), Eterna Therapeutics Inc.'s total revenue was $68,000.00,
and the percentage change from the previous year is not available.
In 2023, Eterna Therapeutics Inc.'s net income was -$21.67 M.
See Eterna Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
Operating Revenue |
$68,000.00 |
$0.00 |
$0.00 |
$0.00 |
$19.81 M |
$23.34 M |
$21.27 M |
$22.31 M |
$24.52 M |
Cost of Revenue |
$236,000.00
|
$497,000.00
|
$459,000.00
|
$98,000.00
|
$7.84 M
|
$8.39 M
|
$7.09 M
|
$8.13 M
|
$13.06 M
|
Gross Profit |
-$168,000.00
|
-$497,000.00
|
-$459,000.00
|
-$98,000.00
|
$11.96 M
|
$14.95 M
|
$14.19 M
|
$14.18 M
|
$11.46 M
|
Gross Profit Ratio |
-2.47
|
0
|
0
|
0
|
0.6
|
0.64
|
0.67
|
0.64
|
0.47
|
Research and Development Expenses |
$5.92 M
|
$10.39 M
|
$12.71 M
|
$3.95 M
|
$26,000.00
|
$72,000.00
|
$139,000.00
|
$0.00
|
$0.00
|
General & Administrative Expenses |
$14.59 M
|
$16.84 M
|
$14.72 M
|
$3.30 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$14.59 M
|
$16.84 M
|
$14.72 M
|
$3.30 M
|
$13.15 M
|
$14.41 M
|
$15.45 M
|
$16.46 M
|
$18.06 M
|
Other Expenses |
$461,000.00
|
-$1.17 M
|
$899,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Operating Expenses |
$20.97 M
|
$27.23 M
|
$27.43 M
|
$7.25 M
|
$13.18 M
|
$14.49 M
|
$15.59 M
|
$16.46 M
|
$18.06 M
|
Cost And Expenses |
$21.20 M
|
$27.23 M
|
$27.43 M
|
$7.25 M
|
$21.02 M
|
$22.87 M
|
$22.68 M
|
$24.59 M
|
$31.12 M
|
Interest Income |
$138,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3,000.00
|
Interest Expense |
$614,000.00
|
$30,000.00
|
$74,000.00
|
$43,000.00
|
$249,000.00
|
$389,000.00
|
$498,000.00
|
$576,000.00
|
$484,000.00
|
Depreciation & Amortization |
$1.12 M
|
$497,000.00
|
$459,000.00
|
$98,000.00
|
$3.17 M
|
$2.76 M
|
$2.32 M
|
$2.89 M
|
$3.10 M
|
EBITDA |
-$19.93 M |
-$33.22 M |
-$121.95 M |
-$7.15 M |
$1.96 M |
$3.23 M |
$915,000.00 |
$609,000.00 |
-$3.63 M |
EBITDA Ratio |
-293.15
|
0
|
0
|
0
|
0.1
|
0.14
|
0.04
|
0.03
|
-0.14
|
Operating Income Ratio |
-310.81
|
0
|
0
|
0
|
-0.06
|
0.02
|
-0.07
|
-0.1
|
-0.27
|
Total Other Income/Expenses Net |
-$536,000.00
|
$8.68 M
|
-$95.05 M
|
-$19.28 M
|
-$808,000.00
|
-$787,000.00
|
$391,001.00
|
-$607,000.00
|
-$614,000.00
|
Income Before Tax |
-$21.67 M
|
-$24.53 M
|
-$122.30 M
|
-$7.29 M
|
-$2.02 M
|
-$323,000.00
|
-$1.01 M
|
-$2.89 M
|
-$7.21 M
|
Income Before Tax Ratio |
-318.69
|
0
|
0
|
0
|
-0.1
|
-0.01
|
-0.05
|
-0.13
|
-0.29
|
Income Tax Expense |
-$3,000.00
|
$45,000.00
|
$5,000.00
|
-$19.20 M
|
$27,000.00
|
-$64,000.00
|
$66,000.00
|
$38,000.00
|
$12,000.00
|
Net Income |
-$21.67 M
|
-$24.58 M
|
-$122.31 M
|
$11.91 M
|
-$2.05 M
|
-$259,000.00
|
-$1.08 M
|
-$2.92 M
|
-$7.23 M
|
Net Income Ratio |
-318.65
|
0
|
0
|
0
|
-0.1
|
-0.01
|
-0.05
|
-0.13
|
-0.29
|
EPS |
-4.08 |
-8.06 |
-56.49 |
27.08 |
-28.48 |
-3.85 |
-17.64 |
-61.44 |
-157.26 |
EPS Diluted |
-4.08 |
-8.06 |
-56.49 |
27.08 |
-28.48 |
-3.85 |
-17.64 |
-61.44 |
-157.26 |
Weighted Average Shares Out |
$5.31 M
|
$3.05 M
|
$2.17 M
|
$439,700.00
|
$71,875.00
|
$67,200.00
|
$61,050.00
|
$47,575.00
|
$45,949.00
|
Weighted Average Shares Out Diluted |
$5.31 M
|
$3.05 M
|
$2.17 M
|
$439,700.00
|
$71,875.00
|
$67,200.00
|
$61,050.00
|
$47,575.00
|
$45,949.00
|
Link |
|
|
|
|
|
|
|
|
|